Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3925388 | 0.85 | ALDH1A1 (0.31) | KDM4EALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL4038265 | 0.84 | KDM4E (0.37) | KDM4EL3MBTL1GAALMNAKMT2A | |
| SCHEMBL3925416 | 0.84 | KDM4E (0.36) | KDM4EL3MBTL1ALDH1A1LMNAKMT2A | |
| SCHEMBL3917759 | 0.82 | NPSR1 (0.39) | KDM4EALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL1800968 | 0.80 | CYP3A4 (0.41) | KDM4EL3MBTL1ALDH1A1GAAKMT2A | |
| SCHEMBL1801173 | 0.80 | ALDH1A1 (0.40) | L3MBTL1ALDH1A1KMT2AMEN1 | |
| SCHEMBL1803451 | 0.79 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL1800500 | 0.79 | MEN1 (0.41) | L3MBTL1ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL1798796 | 0.79 | KMT2A (0.37) | ALDH1A1GAALMNAKMT2AMEN1 | |
| SCHEMBL1800768 | 0.78 | KMT2A (0.43) | KDM4EALDH1A1LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | claimed |
| US-7560468-B2 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | THPO, UGT1A8, UGT1A4 | KDM4E 2581/4885L3MBTL1 4751/4885ALDH1A1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.